Travere Therapeutics (NasdaqGM:TVTX) announced a planned CEO and President transition effective December 1, 2026. Dr. Eric ...
Travere Therapeutics has delivered a very large share price gain over the past few years, which naturally puts the focus on ...
Travere Therapeutics has announced that Bradley L. Campbell will become President and Chief Executive Officer on December 1, 2026, succeeding Eric Dube, Ph.D., who has decided to step down after ...
Eric Dube, Ph.D., the CEO who rebranded Travere Therapeutics and oversaw the launch of its rare kidney disease drug Filspari, will ...
Travere Therapeutics ( ) has issued an announcement. On September 21, 2026, Travere Therapeutics announced that President and Chief Executive Officer Eric Dube, Ph.D., will step d ...
Travere Therapeutics, Inc. und Eric Dube, Ph.D., haben am 21. September 2026 im gegenseitigen Einvernehmen den Zeitplan und ...
Le 21 septembre 2026, Travere Therapeutics, Inc. et Eric Dube, Ph.D., ont convenu d'un commun accord du calendrier et des modalités de la transition prévue du Dr Dube. Ce dernier quittera ...
Investing.com -- Le azioni di Travere Therapeutics Inc ( NASDAQ:TVTX) sono scese fino al 2,3% nelle contrattazioni ...
Travere Therapeutics named Bradley Campbell as president and chief executive officer, effective Dec. 1. Campbell's appointment comes as the biopharmaceutical company's president and CEO Eric Dube ...
Avviso esplicito sui rischi: Il trading degli strumenti finanziari e/o di criptovalute comporta alti rischi, compreso quello ...
Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that company management will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on Thursday, September 24, 2026, at 10:30 a.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results